share_log

The Founder of EuroEyes International Eye Clinic Limited (HKG:1846), Jörn Jörgensen, Just Bought A Few More Shares

Simply Wall St ·  Jul 27, 2022 18:30

Whilst it may not be a huge deal, we thought it was good to see that the EuroEyes International Eye Clinic Limited (HKG:1846) Founder, Jörn Jörgensen, recently bought HK$600k worth of stock, for HK$6.00 per share. Nevertheless, it only increased their shareholding by a minuscule percentage, and it wasn't a massive purchase by absolute value, either.

Check out our latest analysis for EuroEyes International Eye Clinic

The Last 12 Months Of Insider Transactions At EuroEyes International Eye Clinic

In fact, the recent purchase by Founder Jörn Jörgensen was not their only acquisition of EuroEyes International Eye Clinic shares this year. Earlier in the year, they paid HK$11.63 per share in a HK$2.6m purchase. So it's clear an insider wanted to buy, even at a higher price than the current share price (being HK$5.95). While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. In our view, the price an insider pays for shares is very important. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price.

EuroEyes International Eye Clinic insiders may have bought shares in the last year, but they didn't sell any. They paid about HK$8.60 on average. This is nice to see since it implies that insiders might see value around current prices. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

insider-trading-volumeSEHK:1846 Insider Trading Volume July 27th 2022

EuroEyes International Eye Clinic is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. EuroEyes International Eye Clinic insiders own 56% of the company, currently worth about HK$1.1b based on the recent share price. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

So What Do The EuroEyes International Eye Clinic Insider Transactions Indicate?

It's certainly positive to see the recent insider purchases. And the longer term insider transactions also give us confidence. When combined with notable insider ownership, these factors suggest EuroEyes International Eye Clinic insiders are well aligned, and quite possibly think the share price is too low. That's what I like to see! Of course, the future is what matters most. So if you are interested in EuroEyes International Eye Clinic, you should check out this free report on analyst forecasts for the company.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment